IDEAYA Biosciences, Inc.
IDYAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeIDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The $3.47B market capitalization puts IDYA squarely in mid-cap range for its industry. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Market Cap
$3.47B
Beta
-0.09
P/E (TTM)
—
P/E (Fwd)
-9.86
EPS (TTM)
$-1.57
EPS (Fwd)
$-3.65
ROE
-14.3%
ROA
-10.8%
Cash
$671.2M
Total Debt
$28.6M
Free CF
-$57.3M
52W Change
66.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $671.2M in cash comfortably exceeding the $28.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$57.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -14.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $50.9M to $218.7M.
The relatively low beta of -0.09 suggests IDYA is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, IDYA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for IDEAYA Biosciences, Inc. and its sector.